Synapse

← Gordon B. Mills

Papers by Gordon B. Mills

Page 9 · newest first

  1. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial CancerClinical Cancer Research · 2015
  2. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast CancerPLoS ONE · 2015
  3. Metabolic stress induces a Wnt-dependent cancer stem cell-like state transitionCell Death and Disease · 2015
  4. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumoursNature Communications · 2015
  5. Death-associated protein kinase 1 promotes growth of p53-mutant cancersJournal of Clinical Investigation · 2015
  6. Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesCancer Discovery · 2015
  7. Association of Somatic Mutations ofADAMTSGenes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian CarcinomaJAMA Oncology · 2015
  8. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsCancer Discovery · 2015
  9. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical TrialsJournal of Clinical Oncology · 2015
  10. PTEN loss is a context‐dependent outcome determinant in obese and non‐obese endometrioid endometrial cancer patientsMolecular Oncology · 2015
  11. Thematic Review Series: Phospholipases: Central Role in Lipid Signaling and Disease Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progressionJournal of Lipid Research · 2015
  12. Retrospective review of MET gene mutationsOncoscience · 2015
  13. Clinical next generation sequencing to identify actionable aberrations in a phase I programOncotarget · 2015
  14. Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structureCell Cycle · 2015
  15. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2Clinical Cancer Research · 2015
  16. A Decision Support Framework for Genomically Informed Investigational Cancer TherapyJNCI Journal of the National Cancer Institute · 2015
  17. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell CarcinomaJAMA Oncology · 2015
  18. Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic CancerCancer Research · 2015
  19. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaJournal of Clinical Investigation · 2015
  20. Cytoplasmic p27 promotes epithelial–mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulationOncogene · 2015
  21. SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast CancerJNCI Journal of the National Cancer Institute · 2015
  22. Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancerGenome Medicine · 2015
  23. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid TumorsClinical Chemistry · 2015
  24. Prognostic relevance of acquired uniparental disomy in serous ovarian cancerMolecular Cancer · 2015
  25. Functional consequence of theMET-T1010I polymorphism in breast cancerOncotarget · 2014
  26. RET Fusion as a Novel Driver of Medullary Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism · 2014
  27. Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic ImplicationsPLoS ONE · 2014
  28. α-Tubulin Acetylation Elevated in Metastatic and Basal-like Breast Cancer Cells Promotes Microtentacle Formation, Adhesion, and Invasive MigrationCancer Research · 2014
  29. Spatial Normalization of Reverse Phase Protein Array DataPLoS ONE · 2014
  30. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancerJournal of Clinical Investigation · 2014
  31. Mig-6 Suppresses Endometrial Cancer Associated with Pten Deficiency and ERK ActivationCancer Research · 2014
  32. Development of a robust classifier for quality control of reverse-phase protein arraysBioinformatics · 2014
  33. Cupid: simultaneous reconstruction of microRNA-target and ceRNA networksGenome Research · 2014
  34. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patientsOncotarget · 2014
  35. Characterization of HPV and host genome interactions in primary head and neck cancersProceedings of the National Academy of Sciences · 2014
  36. Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in MelanomaCancer Research · 2014
  37. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast CancerClinical Cancer Research · 2014
  38. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseBreast Cancer Research · 2014
  39. A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell CarcinomaMolecular Cancer Therapeutics · 2014
  40. Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial CarcinomaJNCI Journal of the National Cancer Institute · 2014
  41. Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4DMolecular Cancer Therapeutics · 2014
  42. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitorsOncotarget · 2014
  43. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitorsBreast Cancer Research · 2014
  44. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trialJournal of Hematology & Oncology · 2014
  45. The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAFCancer Research · 2014
  46. Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancerBreast Cancer Research · 2014
  47. AKT Pathway Genes Define 5 Prognostic Subgroups in GlioblastomaPLoS ONE · 2014
  48. Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast CancerCancer Research · 2014
  49. A Bayesian hierarchical model for inference across related reverse phase protein arrays experimentsJournal of Applied Statistics · 2014
  50. Influence of Biospecimen Variables on Proteomic Biomarkers in Breast CancerClinical Cancer Research · 2014